- Report
- July 2024
- 245 Pages
Global
From €1732EUR$1,859USD£1,459GBP
€2475EUR$2,655USD£2,084GBP
- Report
- December 2023
- 250 Pages
Global
From €2330EUR$2,499USD£1,962GBP
€3328EUR$3,570USD£2,803GBP
- Report
- October 2022
- 160 Pages
Global
From €2330EUR$2,499USD£1,962GBP
€3328EUR$3,570USD£2,803GBP
- Report
- March 2022
- 254 Pages
Global
From €2326EUR$2,496USD£1,959GBP
€3323EUR$3,565USD£2,799GBP
- Report
- December 2021
- 201 Pages
Global
From €2422EUR$2,598USD£2,040GBP
€3460EUR$3,712USD£2,914GBP
- Report
- April 2022
- 170 Pages
Global
From €2255EUR$2,419USD£1,899GBP
€3222EUR$3,456USD£2,713GBP
- Book
- January 2020
North America

The insulin market is a subset of the larger endocrine and metabolic disorders drugs market. Insulin is a hormone produced by the pancreas that helps regulate the body's blood sugar levels. It is used to treat diabetes, a condition in which the body does not produce enough insulin or is unable to use it effectively. Insulin is available in both short-acting and long-acting forms, and is typically administered via injection or an insulin pump.
The insulin market is highly competitive, with a number of major pharmaceutical companies offering a variety of insulin products. These include Eli Lilly, Novo Nordisk, Sanofi, and Merck. Additionally, there are a number of smaller companies that specialize in the production of insulin, such as Biocon, Wockhardt, and Wockhardt USA. Show Less Read more